Axel Bolte is CEO at Inozyme Pharma, Inc. (INZY). They have made 5 open-market trades across 3 companies since 2013, most recently 2025-07-01.
CIK 0001579247
4 open-market purchases totalling $1.1M since 2013, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| INZY | BUY | 2022-04-19 | 2022-04-20 | $3.69 | $500K | -11.6% | -12.4% | +13.1% |
| OPHT | SELL | 2016-12-30 | 2017-01-23 | $4.83 | $29K | +4.5% | -4.7% | -37.0% |
| OPHT | BUY | 2016-06-03 | 2016-06-07 | $56.97 | $199K | -8.6% | -7.3% | -8.0% |
| OPHT | BUY | 2015-03-30 | 2015-04-01 | $48.27 | $24K | -14.7% | -4.1% | -4.1% |
| OPHT | BUY | 2013-09-25 | 2013-10-07 | $22.00 | $44K | -14.7% | -4.1% | -4.1% |
| PTCT | BUY | 2013-06-25 | 2013-06-27 | $15.00 | $300K | -28.3% | -2.3% | -2.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.